Unravelling the Link between Oligonucleotide Structure and Diastereomer Separation in Hydrophilic Interaction Chromatography.


Journal

Analytical chemistry
ISSN: 1520-6882
Titre abrégé: Anal Chem
Pays: United States
ID NLM: 0370536

Informations de publication

Date de publication:
10 Jun 2024
Historique:
medline: 10 6 2024
pubmed: 10 6 2024
entrez: 10 6 2024
Statut: aheadofprint

Résumé

Therapeutic oligonucleotides (ONs) commonly incorporate phosphorothioate (PS) modifications. These introduce chiral centers and generate ON diastereomers. The increasing number of ONs undergoing clinical trials and reaching the market has led to a growing interest to better characterize the ON diastereomer composition, especially for small interfering ribonucleic acids (siRNAs). In this study, and for the first time, we identify higher-order structures as the major cause of ON diastereomer separation in hydrophilic interaction chromatography (HILIC). We have used conformational predictions and melting profiles of several representative full-length ONs to first analyze ON folding and then run mass spectrometry and HILIC to underpin the link between their folding and diastereomer separation. On top, we show how one can either enhance or suppress diastereomer separation depending on chromatographic settings, such as column temperature, pore size, stationary phase, mobile-phase ionic strength, and organic modifier. This work will significantly facilitate future HILIC-based characterization of PS-containing ONs; e.g., enabling monitoring of batch-to-batch diastereomer distributions in full-length siRNAs, a complex task that is now for the first time shown as possible on this delicate class of therapeutic double-stranded ONs.

Identifiants

pubmed: 38855895
doi: 10.1021/acs.analchem.4c01384
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Honorine Lardeux (H)

School of Pharmaceutical Sciences, University of Geneva, CMU─Rue Michel Servet 1, Geneva 4 1211, Switzerland.
Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU─Rue Michel Servet 1, Geneva 4 1211, Switzerland.

Kathrin Stavenhagen (K)

Medicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 431 83, Sweden.

Clément Paris (C)

Medicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 431 83, Sweden.

Rikke Dueholm (R)

Medicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 431 83, Sweden.

Camille Kurek (C)

Medicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 431 83, Sweden.

Leonardo De Maria (L)

Medicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 431 83, Sweden.

Felix Gnerlich (F)

Medicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 431 83, Sweden.

Tomas Leek (T)

Medicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 431 83, Sweden.

Werngard Czechtizky (W)

Medicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 431 83, Sweden.

Davy Guillarme (D)

School of Pharmaceutical Sciences, University of Geneva, CMU─Rue Michel Servet 1, Geneva 4 1211, Switzerland.
Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU─Rue Michel Servet 1, Geneva 4 1211, Switzerland.

Manasses Jora (M)

Medicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 431 83, Sweden.

Classifications MeSH